What is the price of Imbruvica (ibrutinib) per tablet?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Informasi Harga Imbruvica Tidak Tersedia dalam Literatur Medis

Maaf, informasi mengenai harga Imbruvica (ibrutinib) per tablet tidak tersedia dalam literatur medis, pedoman klinis, atau label obat FDA yang disediakan.

Mengapa Informasi Harga Tidak Tercantum

Literatur medis dan pedoman klinis yang tersedia fokus pada:

  • Efikasi dan keamanan klinis ibrutinib untuk pengobatan Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), dan kondisi lain
  • Dosis yang direkomendasikan: 420 mg per hari untuk CLL 1
  • Profil efek samping dan manajemen toksisitas
  • Analisis cost-effectiveness dari perspektif sistem kesehatan (bukan harga retail per tablet)

Formulasi yang Tersedia

Berdasarkan label FDA, Imbruvica tersedia dalam beberapa formulasi 2:

  • Kapsul: 70 mg dan 140 mg
  • Tablet: 140 mg, 280 mg, 420 mg, dan 560 mg
  • Suspensi oral: 70 mg/mL

Cara Mendapatkan Informasi Harga

Untuk informasi harga aktual per tablet, Anda perlu:

  1. Hubungi apotek lokal atau rumah sakit tempat Anda berencana membeli obat
  2. Konsultasi dengan apoteker mengenai program bantuan pasien atau asuransi kesehatan
  3. Periksa dengan penyedia asuransi Anda untuk mengetahui cakupan dan biaya out-of-pocket
  4. Hubungi produsen (Pharmacyclics LLC/Janssen Biotech) untuk informasi program bantuan pasien

Catatan Penting tentang Biaya

Studi cost-effectiveness menunjukkan bahwa ibrutinib adalah terapi berbiaya tinggi dengan penggunaan berkelanjutan 3, 4. Namun, harga spesifik bervariasi signifikan berdasarkan negara, sistem kesehatan, dan status asuransi pasien.

References

1
Guideline

nccn guidelines insights: chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2017.

Journal of the National Comprehensive Cancer Network : JNCCN, 2017

Related Questions

What are the common and serious side effects of ibrutinib, and how should they be monitored and managed?
Can a 500 mg Robaxin (methocarbamol) tablet be split to achieve a 750 mg dose?
What is the pathophysiology and management of acute pancreatitis?
In a 30-year-old woman at 16 weeks gestation who has autosomal dominant polycystic kidney disease (ADPKD) and a father with ADPKD, should amniocentesis for prenatal diagnosis of ADPKD be performed to guide the decision to continue or terminate the pregnancy?
What is the recommended metoprolol dosing (oral immediate‑release and acute IV) for an adult with supraventricular tachycardia who has no contraindications such as severe asthma, second‑ or third‑degree atrioventricular block, resting heart rate below 60 bpm, systolic blood pressure below 90 mm Hg, or acute decompensated heart failure?
What is the recommended pediatric dosing of metoprolol (immediate‑release) for an acute hemodynamically stable supraventricular tachycardia in a child without contraindications?
How should I manage a 47-year-old male with right knee stiffness who has been taking glucosamine sulfate 750 mg, methylsulfonylmethane 250 mg, and diacerein 50 mg daily for three months with reasonable relief, but now presents with new pain in the left knee?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.